Literature DB >> 3029628

Cerebrospinal fluid concentrations of corticotropin-releasing hormone (CRH) and corticotropin (ACTH) are reduced in patients with Alzheimer's disease.

C May, S I Rapoport, T P Tomai, G P Chrousos, P W Gold.   

Abstract

We examined corticotropin-releasing hormone-like immunoreactivity (CRH-LI) and corticotropin (ACTH) levels in the CSF of 33 patients with presumptive Alzheimer's disease (AD) and 13 healthy, age-matched controls. The mean CRH-LI and ACTH levels of the AD patients were significantly less than controls. Despite these reductions, none of the patients had evidence of pituitary-adrenal dysfunction. A disorder of extrahypothalamic CRH may be involved in the pathophysiology of AD.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3029628     DOI: 10.1212/wnl.37.3.535

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  11 in total

1.  Neurotransmitter markers in the cerebrospinal fluid of normal subjects. Effects of aging and other confounding factors.

Authors:  P Hartikainen; H Soininen; K J Reinikainen; J Sirviö; R Soikkeli; P J Riekkinen
Journal:  J Neural Transm Gen Sect       Date:  1991

Review 2.  Alterations in neuropeptides in aging and disease. Pathophysiology and potential for clinical intervention.

Authors:  A Leake; I N Ferrier
Journal:  Drugs Aging       Date:  1993 Sep-Oct       Impact factor: 3.923

Review 3.  Effects of adrenal cortex hormones on limbic structures: some experimental and clinical correlations related to depression.

Authors:  B Dubrovsky
Journal:  J Psychiatry Neurosci       Date:  1993-01       Impact factor: 6.186

4.  Residues of corticotropin releasing factor-binding protein (CRF-BP) that selectively abrogate binding to CRF but not to urocortin 1.

Authors:  Mark O Huising; Joan M Vaughan; Shaili H Shah; Katherine L Grillot; Cynthia J Donaldson; Jean Rivier; Gert Flik; Wylie W Vale
Journal:  J Biol Chem       Date:  2008-01-29       Impact factor: 5.157

Review 5.  Metabolic and Non-Cognitive Manifestations of Alzheimer's Disease: The Hypothalamus as Both Culprit and Target of Pathology.

Authors:  Makoto Ishii; Costantino Iadecola
Journal:  Cell Metab       Date:  2015-09-10       Impact factor: 27.287

6.  A network model of genomic hormone interactions underlying dementia and its translational validation through serendipitous off-target effect.

Authors:  Erfan Younesi; Martin Hofmann-Apitius
Journal:  J Transl Med       Date:  2013-07-26       Impact factor: 5.531

Review 7.  A preclinical perspective on the enhanced vulnerability to Alzheimer's disease after early-life stress.

Authors:  Lianne Hoeijmakers; Sylvie L Lesuis; Harm Krugers; Paul J Lucassen; Aniko Korosi
Journal:  Neurobiol Stress       Date:  2018-02-23

8.  Neuroprotection of Tropical Fruit Juice Mixture via the Reduction of iNOS Expression and CRH Level in β-Amyloid-Induced Rats Model of Alzheimer's Disease.

Authors:  Theng Choon Ooi; Munirah Ahmad Munawar; Nur Hasnieza Mohd Rosli; Siti Nur Aqilah Abdul Malek; Hanisah Rosli; Farah Wahida Ibrahim; Norazrina Azmi; Hasnah Haron; Razinah Sharif; Suzana Shahar; Nor Fadilah Rajab
Journal:  Evid Based Complement Alternat Med       Date:  2020-04-15       Impact factor: 2.629

9.  Influence of Concentration on Release and Permeation Process of Model Peptide Substance-Corticotropin-From Semisolid Formulations.

Authors:  Wioletta Siemiradzka; Barbara Dolińska; Florian Ryszka
Journal:  Molecules       Date:  2020-06-15       Impact factor: 4.411

Review 10.  Vulnerability and resilience to Alzheimer's disease: early life conditions modulate neuropathology and determine cognitive reserve.

Authors:  Sylvie L Lesuis; Lianne Hoeijmakers; Aniko Korosi; Susanne R de Rooij; Dick F Swaab; Helmut W Kessels; Paul J Lucassen; Harm J Krugers
Journal:  Alzheimers Res Ther       Date:  2018-09-19       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.